A Randomized, Double-Blind (Sponsor-Open), Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Escalating Multiple Doses of TAK-828 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 28 Feb 2017
At a glance
- Drugs TAK 828 (Primary)
- Indications Crohn's disease
- Focus Adverse reactions
- Sponsors Takeda
- 20 Feb 2017 Status changed from active, no longer recruiting to discontinued.
- 03 Nov 2016 Status changed from recruiting to active, no longer recruiting.
- 13 Jul 2016 Status changed from not yet recruiting to recruiting.